Arbutus Biopharma Corporation (ABUS)
NASDAQ·Healthcare·Biotechnology
$4.17
-2.69%
Mkt Cap $830.78M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 23, 2026 | $614.50K | $1.05M | +71.03% | -$0.04 | -$0.01 | +71.47% | — | — |
| Q4 2025 Nov 13, 2025 | $841.00K | $529.00K | -37.10% | -$0.06 | -$0.04 | +28.57% | — | — |
| Q3 2025 Aug 6, 2025 | $1.59M | $10.74M | +574.98% | -$0.02 | $0.01 | +150.00% | — | — |
| Q2 2025 May 14, 2025 | $2.24M | $1.76M | -21.32% | -$0.09 | -$0.13 | -44.44% | — | — |
| Q1 2025 Mar 27, 2025 | $2.26M | $1.57M | -30.26% | -$0.08 | -$0.07 | +12.50% | — | — |
| Q4 2024 Nov 6, 2024 | $1.58M | $1.34M | -15.25% | -$0.10 | -$0.10 | +0.00% | — | — |
| Q3 2024 Aug 1, 2024 | $1.85M | $1.73M | -6.70% | -$0.10 | -$0.11 | -10.00% | — | — |
| Q2 2024 May 2, 2024 | $2.15M | $1.53M | -28.74% | -$0.10 | -$0.10 | +0.00% | — | — |
| Q1 2024 Feb 29, 2024 | $4.79M | $2.15M | -55.22% | -$0.12 | -$0.12 | +0.00% | — | — |
| Q4 2023 Nov 7, 2023 | $4.79M | $4.66M | -2.76% | -$0.12 | -$0.12 | +0.00% | — | — |
| Q3 2023 Aug 3, 2023 | $6.16M | $4.65M | -24.50% | -$0.12 | -$0.10 | +16.67% | — | — |
| Q2 2023 May 4, 2023 | $6.03M | $6.69M | +10.90% | -$0.14 | -$0.10 | +28.57% | — | — |
| Q1 2023 Mar 2, 2023 | $6.18M | $6.25M | +1.13% | -$0.14 | -$0.14 | +0.00% | — | — |
| Q4 2022 Nov 9, 2022 | $9.37M | $5.95M | -36.51% | -$0.12 | -$0.12 | +0.00% | — | — |
| Q3 2022 Aug 4, 2022 | $6.77M | $14.24M | +110.43% | -$0.13 | -$0.10 | +23.08% | — | — |
| Q2 2022 May 5, 2022 | $4.37M | $12.58M | +188.03% | -$0.13 | -$0.11 | +15.38% | — | — |
| Q1 2022 Mar 3, 2022 | $2.88M | $3.21M | +11.21% | -$0.16 | -$0.15 | +6.25% | — | — |
| Q4 2021 Nov 4, 2021 | $2.38M | $3.34M | +40.34% | -$0.24 | -$0.24 | +0.00% | — | — |
| Q3 2021 Aug 5, 2021 | $2.12M | $2.33M | +9.86% | -$0.21 | -$0.23 | -9.52% | — | — |
| Q2 2021 May 5, 2021 | $3.30M | $2.11M | -35.97% | -$0.22 | -$0.21 | +4.55% | — | — |